

November 1, 1965

Dr. William P. Boger  
McNeil Laboratories  
Camp Hill Road  
Fort Washington, Pennsylvania 19034

Dear Bill:

Eighteen months ago you aroused our interest in trifluoperidol and subsequently we undertook a study of this compound in our severely mentally ill. This is the first compound which we studied as an early clinical drug unit. The effects were not as dramatic as had been described and we believe this is largely due to the kind of population which we brought in for this program. It raised some doubts which we voice in the enclosed manuscript and while we are encouraged to continue such studies, it seems to me that we are as likely to miss potent compounds as to identify them unless we develop some special tricks in the analysis.

Dr. Flegel did not come to join us because he had another opportunity in Germany and recently has written that he may have some time late this spring. Unfortunately we have filled all the psychiatrists positions and we are not able to offer him a job at this moment.

I am taking the liberty of enclosing a copy of our manuscript since you are one of those who stimulated our interest in this compound.

Sincerely yours,

Max Fink, M.D.  
Professor of Psychiatry

MF:kp